posted at 04:51
Author: Business Wire
Mon, 30 Jun 2014 11:32:15 +0000
Sedia Biosciences to Present and Exhibit at 2014 International AIDS Conference
Sedia Biosciences Corporation of Portland, Oregon will be presenting its first public results of a new rapid point-of-care HIV incidence assay at the upcoming 20th International AIDS Conference in Melbourne, Australia, July 21-25, 2014. The new assay is expected to augment Sedia's suite of commercial HIV incidence products and further establish Sedia's leadership in the development and manufacture of laboratory assays to monitor the epidemic around the world. The poster presentation will be hosted by Sedia's Director of Product Support and Technical Services, Paul Smith from 12:30 pm to 2:30 pm on Wednesday, July 23, 2014. Mr. Smith stated "This is an exciting new concept incorporating Sedia's rapid test technology with components of the Sedia™ HIV-1 LAg-Avidity EIA to bring HIV incidence testing to resource limited settings. We are currently working with the Centers for Disease Control and Prevention to fully develop this as a new commercial product." The new assay incorporates technology developed by both the CDC and Sedia. Sedia Biosciences will also be exhibiting its products at the Commercial Exhibition Hall of the International AIDS Conference from Sunday, July 20 through Thursday, July 24. Dr. Mink stated, "This conference presents a unique and important opportunity for Sedia to not only present its HIV products to scientists, policymakers and public health officials working in that field, but to also make them aware of our other products and technologies that can further advance their scientific efforts. We look forward to seeing many of our old friends that have partnered with Sedia over the years, but also to making new friends and building new relationships." Sedia Biosciences Corporation is a U.S.-based healthcare company focused on the development and commercialization of novel in vitro diagnostic and epidemiological tests. Based in Portland, Oregon, Sedia develops, manufactures, licenses and sells in vitro diagnostic and epidemiological tests as well as specimen collection devices.

Posts Archive